The Recall Desk
HighFDA (Drugs)·D-0591-2025·Announced 2025-08-27

Sodium bicarbonate injection vials recalled for lack of assurance of sterility

Hospira 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL, lot LH2671, is recalled nationwide for lack of assurance of sterility. 15,750 vials are affected.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Rubric level 3 covers risk-of-harm products where injury has not yet been reported; loss of sterility assurance in an injectable medicine is a potential harm and no injuries are reported.

Plain-English summary

8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL (1 mEq/mL), from Hospira, Inc. of Lake Forest, Illinois, NDC 0409-6637-24 with case NDC 00409-6637-14, is being recalled. The prescription-only product is affected in lot LH2671 with an expiry of 11/30/2026. The recall covers 15,750 vials distributed nationwide.

The recall was issued for lack of assurance of sterility. The FDA classified the action as Class II.

Hospitals and pharmacies holding this lot should quarantine it, stop using it, and follow Hospira's instructions for return or replacement.

The recalled product

Product
SODIUM BICARBONATE (SODIUM BICARBONATE)
Brand
SODIUM BICARBONATE
Manufacturer
PFIZER INC
Affected units
15,750

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot #: LH2671
  • Exp. 11/30/2026

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 2 recalled by PFIZER INC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 2 products in this recall →